Submission Deadline
18 Aug 2022 (Vol 45 , Iss 06 )

Upcoming Publication
31 Aug 2022 (Vol 45 , Iss 06 )

Journal ID : TMJ-06-04-2022-11235
Download [This article belongs to Volume - 45, Issue - 02]
Total View : 407

Title : Vinpocetine attenuates sepsis-induced cardiotoxicity in mice model

Abstract :

Sepsis is a systemic inflammatory consequence resulting from microbial infection, it is assessed as a worldwide healthcare issue, and the main reason for death follows an infection. To explore the possible cardioprotective effects of vinpocetine during sepsis-induced cardiotoxicity. The current study was done with a total of forty male albino Swiss mice, aged 8-12 weeks, and weighing 25-30 gm. These animals had free access to food and water. After two weeks of adaptation, mice were divided into the following four groups (n = 10): (1) Normal group: apparently healthy mice. (2) CLP group: mice underwent CLP operation. (3) Vehicle group: mice received DMSO (4) Vinpocetine group: mice received vinpocetine 30 mg/kg intraperitoneally in 2 divided doses for 5 consecutive days. Vinpocetine group demonstrated a significant (p<0.05) decrease in the myocardial levels of cardiac troponin-I as compared to the CLP group. Furthermore, the vinpocetine group demonstrated a significant (p<0.05) decrease in the serum level of inflammatory cytokines (TNF-α, IL-6, & IL-1β) as compared to the CLP group. Additionally, the vinpocetine group showed a significant (p<0.05) elevation in the myocardial SOD activity and reduction of MDA level as compared to the CLP group. Histologically, All mice in the CLP group showed a significant (p<0.05) cardiac tissue injury, while the vinpocetine group showed a significant (p<0.05) reduced level of cardiac tissue injury. The anti-inflammatory effect through their ability to decrease serum levels of inflammatory cytokines (TNF-α, IL-1β, and IL-6). Also the anti-oxidant effect through their ability to decrease myocardial levels of MDA and increase the myocardial activity of SOD.

Full article
//